# PSMB4

Source: https://onco.cc/targets/psmb4/  
OnCo record `psmb4` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PSMB4 (Proteasome subunit beta type-4) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.

## Summary

Non-catalytic component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. This complex plays numerous essential roles within the cell by associating with different regulatory particles. Associated with two 19S regulatory particles, forms the 26S proteasome and thus participates in the ATP-dependent degradation of ubiquitinated proteins.

Open Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.82, genetic association 0.00, clinical 0.99).

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: proteasome 20S subunit beta 4; Proteasome subunit beta type-4; HN3; PROS26
- Tags: cancer-genes-wave
- Symbol: PSMB4
- Class: other
- Biology: Non-catalytic component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. This complex plays numerous essential roles within the cell by associating with different regulatory particles. Associated with two 19S regulatory particles, forms the 26S proteasome and thus participates in the ATP-dependent degradation of ubiquitinated proteins. The 26S proteasome plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins that could impair cellular functions, and by removing proteins whose functions are no longer required. Associated with the PA200 or PA28, the 20S proteasome mediates ubiquitin-independent protein degradation. This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex). Location: Cytoplasm; Nucleus (UniProt). Locus 1q21.3 (HGNC).
- Where found: Multiple myeloma: Open Targets association 0.61 with plasma cell myeloma (MONDO_0009693); Non-Hodgkin lymphoma: Open Targets association 0.57 with non-Hodgkin lymphoma (MONDO_0018908); Mantle cell lymphoma: Open Targets association 0.54 with mantle cell lymphoma (MONDO_0018876)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.99. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:9541: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9541
- UniProt P28070: https://www.uniprot.org/uniprotkb/P28070/entry
- NCBI Gene 5692: https://www.ncbi.nlm.nih.gov/gene/5692
- Ensembl ENSG00000159377: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000159377

## Connected records

- collections: [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)

---
JSON: https://onco.cc/api/v1/entities/psmb4.json